Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) COO Daryl Gaugler sold 1,106 shares of the stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $61.37, for a total transaction of $67,875.22. Following the completion of the transaction, the chief operating officer now directly owns 11,494 shares in the company, valued at $705,386.78. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ PCRX traded down $2.95 during midday trading on Wednesday, hitting $59.39. The company’s stock had a trading volume of 532,588 shares, compared to its average volume of 525,248. The stock has a fifty day moving average price of $68.89 and a 200 day moving average price of $65.34. Pacira BioSciences, Inc. has a one year low of $45.05 and a one year high of $82.16. The company has a current ratio of 2.19, a quick ratio of 1.85 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $2.70 billion, a price-to-earnings ratio of 70.70 and a beta of 0.89.

Pacira BioSciences (NASDAQ:PCRX – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported $0.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.83 by ($0.19). Pacira BioSciences had a net margin of 6.62% and a return on equity of 15.17%. The business had revenue of $157.99 million during the quarter, compared to the consensus estimate of $155.08 million. During the same period last year, the firm earned $0.37 EPS. The business’s revenue for the quarter was up 32.7% on a year-over-year basis. On average, equities research analysts predict that Pacira BioSciences, Inc. will post 2.88 earnings per share for the current fiscal year.

Several research analysts have weighed in on PCRX shares. StockNews.com started coverage on shares of Pacira BioSciences in a report on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright increased their price target on shares of Pacira BioSciences from $86.00 to $90.00 and gave the company a “buy” rating in a report on Friday, February 25th. TheStreet cut shares of Pacira BioSciences from a “b-” rating to a “c” rating in a report on Thursday, February 24th. Northland Securities increased their price target on shares of Pacira BioSciences from $61.00 to $67.00 in a research report on Tuesday, March 1st. Finally, Wedbush restated a “buy” rating and issued a $94.00 target price (down previously from $97.00) on shares of Pacira BioSciences in a research report on Saturday, February 26th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pacira BioSciences currently has an average rating of “Buy” and an average target price of $80.63.

A number of institutional investors have recently bought and sold shares of PCRX. Wellington Management Group LLP increased its holdings in Pacira BioSciences by 852.7% during the 1st quarter. Wellington Management Group LLP now owns 676,365 shares of the company’s stock worth $51,620,000 after acquiring an additional 605,370 shares during the period. Paulson & CO. Inc. increased its holdings in Pacira BioSciences by 35.4% during the 4th quarter. Paulson & CO. Inc. now owns 1,705,599 shares of the company’s stock worth $102,626,000 after acquiring an additional 446,081 shares during the period. Norges Bank bought a new stake in Pacira BioSciences during the 4th quarter worth approximately $23,557,000. Emerald Advisers LLC bought a new stake in Pacira BioSciences during the 1st quarter worth approximately $23,281,000. Finally, Stonnington Group LLC increased its holdings in Pacira BioSciences by 1,386.6% during the 4th quarter. Stonnington Group LLC now owns 318,829 shares of the company’s stock worth $19,783,000 after acquiring an additional 297,382 shares during the period.

About Pacira BioSciences (Get Rating)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

See Also

Receive News & Ratings for Pacira BioSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pacira BioSciences and related companies with MarketBeat.com’s FREE daily email newsletter.